Prognostic Value of MicroRNA-15a in Human Cancers: A Meta-Analysis and Bioinformatics

Table 5

HRs and 95%CIs of miRNA-15a downregulation in human cancers based on Kaplan-Meier plotter database.

Cancer types	Sample size	HR (95% CI)	P-value
Human cancers	7385	1.17 (0.95-1.44)	0.150
BLCA	408	1.49 (1.11-2.00)	0.0081
BRCA	1076	0.83 (0.58-1.16)	0.27
CSCC	307	0.55 (0.32-0.93)	0.026
ESCA	184	0.53 (0.34-0.85)	0.0072
HNSC	522	1.43 (1.04-1.96)	0.027
KIRC	516	0.78 (0.55-1.09)	0.14
KIRP	290	1.59 (0.84-3.03)	0.15
LIHC	371	1.54 (1.08-2.22)	0.017
LUAD	504	1.23 (0.92-1.67)	0.16
LUSC	472	1.69 (1.22-2.38)	0.0014
OC	485	0.82 (0.65-1.04)	0.10
PAAD	178	2.22 (1.43-3.45)	0.0002
PCPG	179	0.14 (0.02-1.20)	0.038
READ	160	2.63 (1.19-5.88)	0.013
SARC	259	0.69 (0.46-1.04)	0.075
STAD	431	1.52 (1.10-2.08)	0.011
THCA	506	4.17 (0.54-33.33)	0.140
UCEC	537	1.69 (1.10-2.63)	0.015

BLCA, bladder Carcinoma; BRCA, breast cancer; CSCC, cervical squamous cell carcinoma; ESCA, esophageal carcinoma; HNSC, head-neck squamous cell carcinoma; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; OC, ovarian cancer; PAAD, pancreatic ductal adenocarcinoma; PCPG, pheochromocytoma and paraganglioma; READ, rectum adenocarcinoma; SARC, sarcoma; STAD, stomach adenocarcinoma; THCA, thyroid carcinoma; UCEC, uterine corpus endometrial carcinoma.